share_log

Seelos Therapeutics | 10-Q: Q1 2024 Earnings Report

Seelos Therapeutics | 10-Q: Q1 2024 Earnings Report

Seelos Therapeutics | 10-Q：2024财年一季报
美股sec公告 ·  05/14 08:04
Moomoo AI 已提取核心信息
Seelos Therapeutics, Inc. reported a challenging financial quarter ending March 31, 2024, with a decrease in cash from $2.996 million to $524,000. The company's total assets also declined from $5.418 million to $3.612 million. Operating expenses saw a reduction, with research and development costs dropping from $5.668 million to $3.525 million, and general and administrative expenses from $4.072 million to $3.109 million. The net loss for the quarter was $2.664 million, an improvement from the previous year's $13.431 million. The company's future plans include focusing resources on the Phase II study of SLS-002 for acute suicidal ideation and behavior in major depressive disorder patients and the fully enrolled Phase II/III study of SLS-005 in ALS. Seelos also announced a strategic focus on mental health initiatives and a workforce reduction affecting 33% of its employees to reduce operating expenses and extend cash runway. The company faces challenges with maintaining NASDAQ listing requirements, with a recent notice indicating potential delisting due to non-compliance with the minimum bid price requirement and market value of listed securities rule.
Seelos Therapeutics, Inc. reported a challenging financial quarter ending March 31, 2024, with a decrease in cash from $2.996 million to $524,000. The company's total assets also declined from $5.418 million to $3.612 million. Operating expenses saw a reduction, with research and development costs dropping from $5.668 million to $3.525 million, and general and administrative expenses from $4.072 million to $3.109 million. The net loss for the quarter was $2.664 million, an improvement from the previous year's $13.431 million. The company's future plans include focusing resources on the Phase II study of SLS-002 for acute suicidal ideation and behavior in major depressive disorder patients and the fully enrolled Phase II/III study of SLS-005 in ALS. Seelos also announced a strategic focus on mental health initiatives and a workforce reduction affecting 33% of its employees to reduce operating expenses and extend cash runway. The company faces challenges with maintaining NASDAQ listing requirements, with a recent notice indicating potential delisting due to non-compliance with the minimum bid price requirement and market value of listed securities rule.
Seelos Therapeutics, Inc.报告显示，2024年3月31日结束的财务季度面临挑战，现金从299.6万美元下降至52.4万美元。公司的总资产也从541.8万美元下降至361.2万美元。营业费用有所减少，研发成本从566.8万美元降至352.5万美元，一般和管理费用从407.2万美元降至310.9万美元。该季度净亏损为266.4万美元，相较于去年的1343.1万美元有所改善。公司未来计划将资源集中在临床二期研究SLS-002，用于治疗大抑郁症患者的急性自杀倾向和行为，以及在ALS中已招募完毕的SLS-005的临床二/三期研究上。Seelos还宣布战略重点放在心理健康项目上，并缩减33%的员工以减少营业费用并延长现金路径。该公司面临着维持纳斯达克上市的挑战，最近一则通知表明，由于未遵守最低买盘价格要求和已上市证券市值规则，可能面临退市风险。
Seelos Therapeutics, Inc.报告显示，2024年3月31日结束的财务季度面临挑战，现金从299.6万美元下降至52.4万美元。公司的总资产也从541.8万美元下降至361.2万美元。营业费用有所减少，研发成本从566.8万美元降至352.5万美元，一般和管理费用从407.2万美元降至310.9万美元。该季度净亏损为266.4万美元，相较于去年的1343.1万美元有所改善。公司未来计划将资源集中在临床二期研究SLS-002，用于治疗大抑郁症患者的急性自杀倾向和行为，以及在ALS中已招募完毕的SLS-005的临床二/三期研究上。Seelos还宣布战略重点放在心理健康项目上，并缩减33%的员工以减少营业费用并延长现金路径。该公司面临着维持纳斯达克上市的挑战，最近一则通知表明，由于未遵守最低买盘价格要求和已上市证券市值规则，可能面临退市风险。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息